Even though T cell-based checkpoint immunotherapy has revolutionized cancer treatment, the poor immunogenic response of T cell-based immune checkpoint strategies against CTLA-4 and PD-L1 triggers the discovery of novel ‘checkpoints’ on other immune cells, particularly natural killer (NK) cells, which will be targeted in the future [114–116]. Here, CTLA4 is linked to cancer.